comparemela.com

Latest Breaking News On - Sarkis meterissian - Page 1 : comparemela.com

The Laval News | $325,000 donated by Pink in the City to MUHC s Breast Clinic Wellness program

$325,000 donated by Pink in the City to MUHC’s Breast Clinic Wellness program | The Laval News | Serving Laval Since 1993

Lawrence vourtzoumisMary derosPaolo galatiSarkis meterissianPlouffe vasilios karidogiannisMartinc barryDenise vourtzoumisBobby vourtzoumiZoe scappaticcioAlejandro gutierrezTony loffredaLaval senior academySir wilfrid laurier school boardMcgill university health centreBreast clinic wellnessLaval news

New impulse for the Quebec Metastatic Breast Cancer Registry | McGill University Health Centre

The Registry, which is an initiative of the McPeak-Sirois Group under the leadership of Dr. Sarkis Meterissian, is expanding thanks to the financial support of the Canadian Cancer Society.

Sarkis meterissianQuebec cancer screening programCanadian cancer societyCancer research programQuebec breast cancer foundationResearch instituteSirois group theMcgill universityMcgill university health centreSirois groupMcpeak sirois groupCanadian cancerBreast cancer clinicQuebec metastatic breast cancer registryQuebec breast cancerDes services

The Canadian Cancer Society and the McPeak-Sirois Group team up to improve metastatic breast cancer research and care

/CNW/ - The Canadian Cancer Society (CCS) and the McPeak-Sirois Group (the Group), one of the largest breast cancer clinical research consortia in Canada, are.

Dominique johnsonCharles siroisStuart edmondsJack malcolm samediFabienne landrySarkis meterissianSusan mcpeakCommunications advisorCanadian cancer societyQuebec cancer screening programQuebec breast cancer foundationCanadian cancer society national officeAdvocacy for the canadian cancer societyMcgill university health centreSirois groupCommunications coordinator

Original-Research: Defence Therapeutics Inc (von GBC AG): -

Original-Research: Defence Therapeutics Inc. - von GBC AG Einstufung von GBC AG zu Defence Therapeutics Inc. Unternehmen: Defence Therapeutics Inc. ISIN: CA24463V1013 Anlass der Studie: Research

Julien desrosiersCosmin filkerSebastien plouffeSarkis meterissianSimon beaudoinMoutih rafeiResearch watchlistDefence therapeutics incInnovation centre university of albertaBreast centerResearch commentHead of the tumor site groupDrug developmentDefence therapeuticsInvestment advisorTumor site group

Original-Research: Defence Therapeutics Inc (von GBC AG)

Original-Research: Defence Therapeutics Inc. - von GBC AGEinstufung von GBC AG zu Defence Therapeutics Inc.Unternehmen: Defence Therapeutics Inc.ISIN: CA24463V1013Anlass der Studie: Research CommentEmpfehlung: -Kursziel: -Letzte Ratingänderung: Analyst: Julien Desrosiers, Cosmin FilkerGBC Research Watchlist: Defence.

Julien desrosiersCosmin filkerSebastien plouffeSarkis meterissianSimon beaudoinMoutih rafeiResearch watchlistDefence therapeutics incInnovation centre university of albertaBreast centerResearch comment empfehlungHead of the tumor site groupDrug developmentDefence therapeuticsInvestment advisorTumor site group

vimarsana © 2020. All Rights Reserved.